Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents
Portfolio Pulse from Benzinga Newsdesk
Genevant Sciences and Arbutus Biopharma have won the dismissal of a legal action by Acuitas Therapeutics, which is partnered with Pfizer on vaccine delivery systems. The action sought a declaratory judgment that Pfizer's Comirnaty vaccine does not infringe on Arbutus patents.
May 20, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's partner, Acuitas Therapeutics, has lost a legal action seeking a declaratory judgment that the Comirnaty vaccine does not infringe on Arbutus patents.
The dismissal of the action could imply potential future legal challenges for Pfizer regarding its Comirnaty vaccine, which may have a short-term negative impact on its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Arbutus Biopharma has won a legal battle, with the court dismissing Acuitas Therapeutics' action seeking a declaratory judgment that Pfizer's Comirnaty vaccine does not infringe on Arbutus patents.
The dismissal of the legal action is a positive development for Arbutus Biopharma, as it removes a potential legal hurdle and reinforces the strength of its patent portfolio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100